HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.
HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.